



# A highly stereocontrolled and efficient synthesis of $\alpha$ - and $\beta$ -pseudouridines

Stephen Hanessian\* and Roger Machaalani

Department of Chemistry, Université de Montréal, C. P. 6128, Succ. Centre-Ville, Montréal, P. Q., Canada, H3C 3J7

Received 20 August 2003; accepted 4 September 2003

**Abstract**—A five-step practical and stereocontrolled synthesis of  $\alpha$ - and  $\beta$ -pseudouridines from D-ribonolactone is described. The key step involves a highly stereoselective reduction of a hemiketal C-nucleoside intermediate in each case. Multi-gram quantities of  $\beta$ -pseudouridine can now be made available.  
© 2003 Elsevier Ltd. All rights reserved.

The ubiquitous presence of  $\beta$ -pseudouridine **1** (Fig. 1), a C-5  $\beta$ -linked uridine in rRNA and tRNA of bacterial and mammalian origins has instigated numerous studies concerned with its functional relevance.<sup>1</sup> The occurrence of pseudouridine in highly conserved regions of the RNA superstructure reflects on its importance in molecular recognition phenomena dealing with polypeptide synthesis for example.<sup>2</sup> This and other observations of biological significance have resulted in studies aimed at the incorporation of synthetic C-nucleosides consisting of aromatic and heteroaromatic aglycones in various RNAs and DNAs.<sup>3</sup> The cytotoxic activity of aromatic C-nucleosides has been known for some time.<sup>4</sup>  $\beta$ -Pseudouridine has been recently reported as an antimutagenic substance in beer.<sup>5</sup>


As already commented on elsewhere,<sup>6</sup> the exploitation of the potentially important roles that  $\beta$ -pseudouridine can play in the RNA field has been hampered by its limited availability and prohibitive cost. Only recently

have methods been developed to access C-nucleosides in preparatively significant amounts.<sup>3,4,6</sup> These have been extended to pyrimidine bases resulting in a practical 7-step synthesis of  $\beta$ -pseudouridine from readily available materials such as ribonolactone.<sup>6</sup> In spite of these improvements, a 1:1 mixture of anomeric C-nucleosides is obtained as a result of a non-selective reduction of a lactol intermediate with triethylsilane.<sup>7</sup>

We report herein, a practical, and most importantly, a highly stereoselective synthesis of  $\beta$ -pseudouridine in 5-steps with an overall yield of 46% starting with D-ribonolactone. The method is also applicable to the synthesis of  $\alpha$ -pseudouridine.

Treatment of D-ribonolactone **3** with 2,2-dimethoxypropane in the presence of pyridinium *p*-toluenesulfonate and sodium sulfate gave the protected bis-acetal **4** in 94% isolated yield (Scheme 1).<sup>8</sup> Addition of 5-lithio-2,4-di-*t*-butoxypyrimidine **5**<sup>6b</sup> to **4** in THF at  $-78^{\circ}\text{C}$  gave the adduct **6** as a 1:8  $\alpha/\beta$ -mixture in 89% yield. The latter, in equilibrium with its hydroxyketone isomer (not shown) was reduced with L-Selectride (3.4 equiv.) in the presence of  $\text{ZnCl}_2$  (1.36 equiv.) to give the acyclic D-*altro*-hexitol **7** as a single isomer in 85% yield. Cycloetherification under Mitsunobu conditions<sup>9</sup> with diisopropyl azodicarboxylate (DIAD) and triphenylphosphine gave **8** in 70% yield. Finally, deprotection with 70% acetic acid gave  $\beta$ -pseudouridine in 93% yield, identical with an authentic sample. This constitutes the shortest synthesis of  $\beta$ -pseudouridine which can now be prepared in multi-gram quantities.<sup>10</sup>


The anomeric  $\alpha$ -pseudouridine **2**,<sup>6b</sup> was synthesized essentially using the same protocol, except that the



**Figure 1.** Structures of  $\alpha$ - and  $\beta$ -pseudouridine.

**Keywords:** C-nucleoside; cycloetherification; selective reductions.


\* Corresponding author.



Scheme 2.

as described above gave  $\alpha$ -pseudouridine **2** with an overall yield of 66%. It is of interest that the Mitsunobu cyclization was faster and more efficient in the case of **9** compared to **7**, probably due to a lower steric barrier.<sup>11</sup>

In an earlier version of the synthesis where 2,4-dimethoxypyrimidine was the aglycone, hydrolysis with NaI/TMSCl (MeCN, 16 h) according to a literature procedure<sup>12</sup> (or with 70% AcOH, 30% HBr in AcOH, reflux 1 h) led to considerable anomerization. Related epimerizations have been recently reported for aromatic C-nucleosides under mild acidic conditions.<sup>13</sup> A plausible mechanism is shown in Scheme 3.



Scheme 3.




Figure 2. Possible pathways for stereoselective reductions.

The remarkably stereoselective reduction of the lactol **6** with L-Selectride in the presence or absence of zinc chloride can be rationalized by invoking chelated and non-chelated intermediates, respectively as illustrated in Figure 2. Chelation of the divalent zinc with the ketone carbonyl and the acetal oxygen allows hydride delivery from the *Si* (pro-*S*) face to give the observed D-*altro* isomer **7**. In the absence of chelation, the *Re*(pro-*R*)-face of the carbonyl is better exposed to receive the bulky hydride. The influence of the protective groups on the heterocycle (ex. 2-*C*-benzimidazolyl; 2-*C*-imidazolyl, etc.) on the selectivity of reductions of *C*-heterocyclic lactols with NaBH<sub>4</sub>, has been reported.<sup>9a</sup>

The extension of this new method to the stereoselective synthesis of other *C*-nucleosides is currently in progress.

### Acknowledgements

We thank NSERC, Syngenta Crop Protection (UK) for generous financial support through the Medicinal Chemistry Chair Program.

### References

1. For a review, see Maden, B. E. H. *Nature* **1997**, 389, 129.
2. Lane, B. G.; Ofengand, J.; Gray, M. W. *Biochimie* **1995**, 77, 7.
3. See, for example: (a) Schweitzer, B. A.; Kool, E. T. *J. Org. Chem.* **1994**, 59, 7238; (b) Hildbrand, S.; Leumann, C. *Angew. Chem. Int. Ed.* **1996**, 35, 1968; (c) Matulic-Adamic, J.; Beigelman, L. *Tetrahedron Lett.* **1997**, 38, 1669; (d) Parsch, J.; Engels, J. W. *Helv. Chim. Acta* **2000**, 83, 1791.
4. Krohn, K.; Heins, H.; Wielckens, K. *J. Med. Chem.* **1992**, 35, 511.
5. Yoshikawa, T.; Kimura, S.; Hatano, T.; Okamoto, K.; Hayatsu, H.; Arimoto-Kobayashi, S. *Food Chem. Toxicol.* **2002**, 40, 1165; see also, Monobe, M.; Arimoto-Kobayashi, S.; Ando, K. *Mutation Res.* **2003**, 538, 93.
6. (a) Grohen, P. J.; Chow, C. S. *Tetrahedron Lett.* **1999**, 40, 2049; (b) For earlier syntheses of  $\alpha$ - and  $\beta$ -pseudouridines, see Brown, D. M.; Ogden, R. C. *J. Chem. Soc., Perkin Trans. 1* **1981**, 723 and references cited therein.
7. Rolf, D.; Gray, G. R. *J. Am. Chem. Soc.* **1982**, 104, 3539.
8. The original procedure without the inclusion of sodium sulfate gave **4** in 40% yield, accompanied by the protected  $\delta$ -lactone and 2,3-*O*-isopropylidene-D-ribonolactone, see Csuk, R.; Kühn, M.; Ströhl, D. *Tetrahedron* **1997**, 53, 1311. See Scheme 1 for the optimized and modified procedure.
9. (a) Guianvarc'h, D.; Fourrey, J.-L.; Tran Huu Dau, M.-E.; Guérineau, V.; Benhida, R. *J. Org. Chem.* **2002**, 67, 3724; for reviews, see (b) Mitsunobu, O. *Synthesis* **1981**, 1; (c) Hughes, D. C. *Org. React.* **1992**, 42, 335.
10. Typical procedure **6**→**8** for  $\beta$ -pseudouridine.  
**7**: To **6** (450 mg, 0.93 mmol) in dry DCM (36 mL) at  $-78^{\circ}\text{C}$ , was added ZnCl<sub>2</sub> (1.26 mL, 1.26 mmol, 1 M in Et<sub>2</sub>O) and the mixture was stirred for 30 min. L-Selectride (3.16 mL, 3.16 mmol, 1 M in THF) was then added dropwise and portionwise for a period of 30 min at  $-78^{\circ}$ . Mixture was then slowly brought to room temperature and stirred overnight. The white heterogeneous solution was quenched with EtOH (0.54 mL), H<sub>2</sub>O (0.120 mL), NaOH 6M (0.47 mL) and H<sub>2</sub>O<sub>2</sub> 30% (0.47 mL). It was then stirred for 30 min and diluted with EtOAc (50 mL) and H<sub>2</sub>O (50 mL). Usual workup gave a colorless oil which was purified by flash chromatography (1:1 hexanes/EtOAc) to give **7** as a white foamy solid (385 mg, 85%);  $R_f$ =0.35 (1:1 hexanes/EtOAc), m.p. 40–42°C,  $[\alpha]_D$   $-50.64^{\circ}$  (c 0.23, MeOH). **8**: To **7** (155 mg, 0.32 mmol) in dry THF (33 mL) was added Ph<sub>3</sub>P (168 mg, 0.64 mmol). The colorless mixture was cooled to 0°C and DIAD (0.126 mL, 0.64 mmol) was added, stirred at 4°C for 48 h, then brought to room temperature and concentrated. The yellow oil was purified by flash chromatography (2:1 hexanes/EtOAc) to give **8** as a colorless oil (105 mg, 70%);  $R_f$ =0.72 (1:1 hexanes/EtOAc);  $[\alpha]_D$   $+12.0^{\circ}$  (c 8.5, MeOH).
11. Typical procedure **6**→**9**→**10** for  $\alpha$ -pseudouridine.  
**9**: To **6** (500 mg, 1.03 mmol) in dry THF (40 mL) at  $-78^{\circ}\text{C}$ , was added L-Selectride (3.5 mL, 3.5 mmol, 1 M in THF) dropwise and portionwise for a period of 30 min. Mixture was then slowly brought to room temperature and stirred overnight, concentrated and dissolved with DCM (40 mL). EtOH (0.54 mL), H<sub>2</sub>O (0.120 mL), NaOH 6M (0.47 mL) and H<sub>2</sub>O<sub>2</sub> 30% (0.47 mL) were added and stirred for 30 min, then diluted with EtOAc (50 mL) and H<sub>2</sub>O (50 mL). Usual workup gave a colorless oil which was purified by flash chromatography (1:1 hexanes/EtOAc) to give **9** as a white foamy solid (430 mg, 88%);  $R_f$ =0.32 (1:1 hexanes/EtOAc), m.p. 43–45°C,  $[\alpha]_D$   $+8.35^{\circ}$  (c 0.46, MeOH).  
**10**: To **9** (350 mg, 0.72 mmol) in dry THF (75 mL) was added Ph<sub>3</sub>P (378 mg, 1.44 mmol). The colorless mixture was cooled to 0°C and DIAD (0.28 mL, 1.44 mmol) was added. Mixture was stirred at 4°C for 24 h then brought to room temperature and concentrated. The yellow oil was purified by flash chromatography (2:1 hexanes/EtOAc) to give **10** as a colorless oil (305 mg, 90%);  $R_f$ =0.74 (1:1 hexanes/EtOAc);  $[\alpha]_D$   $-37.2^{\circ}$  (c 0.5, MeOH).
12. (a) Kundu, N. G.; Das, B.; Spears, P.; Majundar, A.; Kang, S.-I. *J. Med. Chem.* **1990**, 33, 1975; (b) Morita, T.; Okamoto, Y.; Sakurai, H. *J. Chem. Soc., Chem. Commun.* **1978**, 874; (c) Silverman, R. B.; Radak, R. E.; Hacker, N. P. *J. Org. Chem.* **1979**, 44, 4970.
13. Jiang, Y. L.; Stivers, J. T. *Tetrahedron Lett.* **2003**, 44, 4051.